---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-036408"
form_type: "8-K"
ticker: "AIM"
cik: "0000946644"
company_name: "AIM ImmunoTech Inc."
filed_at: "2026-08-06T21:22:52+00:00"
generated_at: "2026-08-06T21:24:47.814971+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# AIM ImmunoTech enters $1.5M manufacturing agreement with Sterling Pharma for Ampligen drug substance

## Summary
- Agreement with Sterling Pharma Solutions to manufacture PolyI and Poly C12U (precursors to Ampligen) at Dudley, UK site.
- Estimated cost ~$1.5M over 12 months; includes process development, non-GMP demo batches, analytical method validation, and one cGMP batch each.
- Product intended for ongoing and future clinical trials, including potential Phase 3 for metastatic pancreatic cancer.
- Shareholder director nominations for 2026 annual meeting must be received between Aug 18 and Sep 17, 2026; universal proxy deadline Oct 19, 2026.

## SEC filing metadata
- accession: 0001493152-26-036408
- form_type: 8-K
- ticker: AIM
- cik: 0000946644
- company_name: AIM ImmunoTech Inc.
- filed_at: 2026-08-06T21:22:52+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 5.08, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946644/000149315226036408/0001493152-26-036408-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946644/000149315226036408/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-036408
- JSON: https://secwatch.observer/filing/0001493152-26-036408.json
- Plain text: https://secwatch.observer/filing/0001493152-26-036408.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.